Danaher Co. (NYSE:DHR) Shares Sold by Simon Quick Advisors LLC

Simon Quick Advisors LLC lessened its position in shares of Danaher Co. (NYSE:DHR) by 4.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,369 shares of the conglomerate’s stock after selling 191 shares during the quarter. Simon Quick Advisors LLC’s holdings in Danaher were worth $1,003,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Fort Pitt Capital Group LLC grew its position in Danaher by 3.2% during the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after buying an additional 7,421 shares during the period. Good Life Advisors LLC acquired a new stake in Danaher during the third quarter valued at $217,000. ORG Partners LLC grew its position in Danaher by 1,212.8% during the fourth quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock valued at $636,000 after buying an additional 2,559 shares during the period. Harvest Portfolios Group Inc. grew its position in shares of Danaher by 1.2% in the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock valued at $56,233,000 after purchasing an additional 2,465 shares during the period. Finally, Stifel Financial Corp grew its position in shares of Danaher by 1.3% in the third quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after purchasing an additional 11,216 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $244.19 on Thursday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm has a market capitalization of $176.38 billion, a price-to-earnings ratio of 46.60, a PEG ratio of 4.30 and a beta of 0.83. The company’s 50-day moving average is $234.84 and its two-hundred day moving average is $253.53. Danaher Co. has a 1-year low of $225.42 and a 1-year high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the business posted $2.02 EPS. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year. Analysts forecast that Danaher Co. will post 7.49 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio is currently 20.61%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Raymond James dropped their target price on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a research report on Tuesday. Citigroup dropped their target price on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Scotiabank assumed coverage on shares of Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price on the stock. Royal Bank of Canada dropped their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Finally, Barclays dropped their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.